

Supplementary Tables

Supplementary Table 1: Baseline Characteristics and Outcomes for DVT-prophylaxis only versus UFH cohorts of ECMO patients

| Characteristics | DVT prophylaxis only (n = 42) | UFH (n = 135) | P value | SMD |
|-----------------------------|----------------------------------|---------------------|---------|-------|
| Age (yr), median [IQR] | 59.00 [45.00–68.75] | 55.00 [43.50–64.50] | 0.26 | 0.17 |
| Female, n (%) | 16 (38%) | 36 (27%) | 0.18 | 0.25 |
| Past medical history | | | | |
| Atrial fibrillation | 12 (29%) | 11 (8%) | 0.001 | 0.55 |
| Heart failure | 8 (19%) | 26 (19%) | 1 | 0.005 |
| CKD | 1 (2%) | 14 (10%) | 0.12 | 0.33 |
| COPD | 1 (2%) | 4 (3%) | 1 | 0.04 |
| ILD | 1 (2%) | 1 (1%) | 0.42 | 0.13 |
| CVA | 8 (19%) | 13 (10%) | 0.11 | 0.27 |
| DLD | 22 (52%) | 42 (31%) | 0.02 | 0.44 |
| DM | 14 (33%) | 34 (25%) | 0.32 | 0.18 |
| GIB | 0 (0%) | 1 (1%) | 1 | 0.17 |
| HTN | 21 (50%) | 57 (42%) | 0.38 | 0.16 |
| PVD | 2 (5%) | 3 (2%) | 0.34 | 0.14 |
| Previous cardiac surgery | 8 (19%) | 38 (28%) | 0.32 | 0.22 |
| Smoking (current) | 4 (10%) | 22 (16%) | 0.60 | 0.20 |
| Smoking (past) | 12 (29%) | 37 (27%) | 0.60 | 0.20 |
| Precannulation labs | | | | |
| PO ₂ | 132 [67–320] | 119 [63–294] | 0.49 | 0.08 |
| PCO ₂ | 44 [35–52] | 41 [36–50] | 0.50 | 0.05 |
| Creatinine | 120 [90–174] | 124 [84–178] | 0.90 | 0.04 |
| Hematocrit | 28 [25–36] | 30 [25–36] | 0.87 | 0.02 |
| Sodium | 138 [135–147] | 140 [137–145] | 0.7 | 0.003 |
| Potassium | 4.4 [3.8–5.5] | 4.1 [3.7–4.6] | 0.03 | 0.45 |
| Home Anticoagulants | | | | |
| ASA | 16 (38%) | 53 (39%) | 1 | 0.02 |
| NOAC | 2 (5%) | 2 (2%) | 0.24 | 0.19 |
| Clopidogrel/ticagrelor | 4 (10%) | 10 (7%) | 0.74 | 0.08 |
| Warfarin | 10 (24%) | 14 (10%) | | |
| Type of ECMO | | | | |
| VA ECMO | 36 (86%) | 100 (74%) | 0.14 | 0.29 |
| VV ECMO | 6 (14%) | 35 (26%) | 0.14 | 0.29 |

| MCS indication | | | | |
|---------------------------------|------------|-----------|-------|------|
| Cardiac arrest | 14 (33%) | 31 (23%) | 0.53 | 0.37 |
| Post heart transplant support | 5 (12%) | 17 (13%) | | |
| Postcardiotomy | 13 (31%) | 48 (36%) | | |
| Respiratory failure | 7 (17%) | 34 (25%) | | |
| Post PCI | 1 (2%) | 2 (2%) | | |
| Toxicologic overdose | 0 (0%) | 1 (1%) | | |
| Hypothermic rewarm | 1 (2%) | 1 (1%) | | |
| Thrombotic Complications | | | | |
| LV thrombus | 1 (2%) | 1 (1%) | 0.42 | 0.13 |
| Clots in circuit | 9 (21%) | 38 (28%) | 0.43 | 0.16 |
| Pump thrombosis | 0 (0%) | 1 (1%) | 1 | 0.12 |
| Ischemic stroke | 2 (5%) | 1 (1%) | 0.14 | 0.25 |
| Bleeding complications | | | | |
| BARC \geq 2 | 19 (45%) | 76 (56%) | 0.22 | 0.22 |
| Re-exploration for bleeding | 17 (40%) | 59 (44%) | 0.86 | 0.06 |
| Total pRBCs | 24 [15–42] | 24 [9–39] | 0.55 | 0.08 |
| Course in hospital | | | | |
| Survival to discharge | 5 (12%) | 53 (39%) | 0.001 | 0.66 |

ASA = acetylsalicylic acid; BARC = Bleeding Academic Research Consortium; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CVA = cerebrovascular accident; DLD = dyslipidemia; DM = diabetes mellitus; DVT = deep vein thrombosis; ECMO = extracorporeal membrane oxygenation; GIB = gastrointestinal bleed; HTN = hypertension; ILD = interstitial lung disease; LOS = length of stay; LV = left ventricle; MCS = mechanical circulatory support; NOAC = non-vitamin K antagonist oral anticoagulant; PCI = percutaneous intervention; pRBCs = packed red blood cells; PVD = peripheral vascular disease; SMD = standardized mean difference; UFH = unfractionated heparin; VA = venoarterial; VV = venovenous